HOWARU® Bi-07®
HOWARU® Bifidobacterium lactis Bi-07® functions harmoniously with other strains like NCFM®, Lpc-37®, and Bl-04® in our HOWARU® Restore blend. Together, they support gut health, lessen the days of gut disruption and support overall digestive health.¹ In two other blends—HOWARU® Protect Kids and HOWARU® Protect Sport—B. lactis Bi-07® has been clinically studied in combination with NCFM® supporting immune function.²
- ~70 preclinical publications
- 60+ clinical publications
Early Life Development
Bi-07® CLINICAL STUDIES & PUBLICATIONS
Extensive in vitro and in vivo studies support the health-enhancing, probiotic properties of B. lactis Bi-07®. The strain has been investigated in more than 140 scientific publications, including more than 60 clinical trial publications that extend from infants (7 months of age) to aging populations (70 years of age). Bi-07® has a long history of safe use, is well suited for intestinal survival, and has strong adhesion to intestinal cell lines.³⁻⁹
Health Benefit Areas
Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies.
Click on a Health Benefit to see more studies and learn more.
-
Supporting Daily Dose: 17B CFU Bl-04®, NCFM®, Bi-07®, Lpc-37®
Study Reference: Ouwehand AC, et al. Vaccine. 2014;32(4):458-463. - Supporting Daily Dose: 10B CFU Total Bi-07®, Bl-04®, NCFM®, Lpc-37®
Study Reference: van Zanten G, et al. Microorganisms. 2024; 12(4),796.
Supporting Daily Dose: 10B CFU (equal parts) Bi-07®, NCFM®
Study Reference:
References: 1. Ouwehand AC et al.; Vaccine. 2014; 2. Leyer GJ et al.;Pediatrics. 2009; 3. Candela M et al.; J Bacteriol. 2007; 4. Candela M et al.; Microbiology. 2009; 5. Candela M, et al.; Microbiology. 2008; 6. Candela M, et al.; Int J Food Microbiol. 2008; 7. Candela M et al.; J Microbiol Methods. 2008; 8. Candela M et al.; Res. Microbiol. 2005; 9. Candela M et al.; Appl Environ Microbiol. 2011
